Abstract P083 – Table 1. Proportions of participants with CVF, blips, or HIV‐1 RNA ≥50 copies/mL through week 96.
Treatment group	Participants with CVF through W96	Participants with HIV‐1 blipa at any study visit	Participants with HIV‐1 RNA ≥50 copies/mL at W96 (FDA Snapshot)	Participants without HIV‐1 blipa and HIV‐1 RNA ≥50 copies/mL at W96	Participants with HIV‐1 blipa and HIV‐1 RNA ≥50 copies/mL at W96	CVF participants with HIV‐1 blipa through W96
Q4W CAB+RPV LA	4/283 (1%)	45/283 (16%)	9/283 (3%)	7/238 (3%)	2/45 (4%)	0/45
Oral three‐drug SOC	4/283 (1%)	48/283 (17%)	9/283 (3%)	6/235 (3%)	3/48 (6%)	1/48 (2%)

^aHIV‐1 RNA between 50 and <200 copies/mL with adjacent values <50 copies/mL.